Patents by Inventor Charles R. Cantor
Charles R. Cantor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8304194Abstract: The present invention relates to a method for measuring the amount of a target nucleic acid in a sample using a standard which is designed to have one base difference compared with the gene of interest or a “target nucleic acid sequence.” Use of such standard in combination with a method of “enhancing” the difference in the standard and the test nucleic acid sample using, for example, a base extension reaction carried right at the mutation site allowing amplification of the standard and target nucleic acids with the same efficiency and facilitating quantification of the target nucleic acid. Thereafter a means of quantifying the “enhanced” standard and target nucleic acid samples is used to determine the amount of the target nucleic acid. In the preferred embodiment, the quantification means is Mass Spectrometry.Type: GrantFiled: September 1, 2011Date of Patent: November 6, 2012Assignee: The Trustees of Boston UniversityInventors: Charles R. Cantor, Chunming Ding
-
Publication number: 20120225798Abstract: The present invention is directed to methods of detecting nucleic acids in a biological sample. The method is based on a novel combination of a base extension reaction, which provides excellent analytical specificity, and a mass spectrometric analysis, which provides excellent specificity. The method can be used, for example, for diagnostic, prognostic and treatment purposes. The method allows accurate detection of nucleic acids that are present in very small amounts in a biological sample. For example, the method of the present invention is preferably used to detect fetal nucleic acid in a maternal blood sample; circulating tumor-specific nucleic acids in a blood, urine or stool sample; and donor-specific nucleic acids in transplant recipients. In another embodiment, one can detect viral, bacterial, fungal, or other foreign nucleic acids in a biological sample.Type: ApplicationFiled: February 8, 2012Publication date: September 6, 2012Applicant: THE TRUSTEES OF BOSTON UNIVERSITYInventors: Charles R. Cantor, Chunming Ding, Yuk Ming Dennis Lo, Rossa Wai Kwum Chiu
-
Publication number: 20120184449Abstract: Provided herein are fetal diagnostic methods, kits and computational products useful for non-invasively detecting genetic variations for which maternal nucleic acid sequences are utilized as a reference.Type: ApplicationFiled: December 21, 2011Publication date: July 19, 2012Applicant: SEQUENOM, INC.Inventors: Harry F. HIXSON, Charles R. CANTOR
-
Publication number: 20120156685Abstract: The present invention is directed to a method for detecting and quantifying rare mutations in a nucleic acid sample. The nucleic acid molecules under investigation can be either DNA or RNA. The rare mutation can be any type of functional or non-functional nucleic acid change or mutation, such as deletion, insertion, translocation, inversion, one or more base substitution or polymorphism. Therefore, the methods of the present invention are useful in detection of rare mutations in, for example, diagnostic, prognostic and follow-up applications, when the targets are rare known nucleic acid variants mixed in with the wildtype or the more common nucleic acid variant(s).Type: ApplicationFiled: March 6, 2012Publication date: June 21, 2012Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Charles R Cantor, Chunming Ding
-
Patent number: 8153377Abstract: The present invention is directed to a method for detecting and quantifying rare mutations in a nucleic acid sample. The nucleic acid molecules under investigation can be either DNA or RNA. The rare mutation can be any type of functional or non-functional nucleic acid change or mutation, such as deletion, insertion, translocation, inversion, one or more base substitution or polymorphism. Therefore, the methods of the present invention are useful in detection of rare mutations in, for example, diagnostic, prognostic and follow-up applications, when the targets are rare known nucleic acid variants mixed in with the wildtype or the more common nucleic acid variant(s).Type: GrantFiled: July 1, 2009Date of Patent: April 10, 2012Assignee: Trustees of Boston UniversityInventors: Charles R Cantor, Chunming Ding
-
Publication number: 20120028838Abstract: The present invention relates to a method for measuring the amount of a target nucleic acid in a sample using a standard which is designed to have one base difference compared with the gene of interest or a “target nucleic acid sequence.” Use of such standard in combination with a method of “enhancing” the difference in the standard and the test nucleic acid sample using, for example, a base extension reaction carried right at the mutation site allowing amplification of the standard and target nucleic acids with the same efficiency and facilitating quantification of the target nucleic acid. Thereafter a means of quantifying the “enhanced” standard and target nucleic acid samples is used to determine the amount of the target nucleic acid. In the preferred embodiment, the quantification means is Mass Spectrometry.Type: ApplicationFiled: September 1, 2011Publication date: February 2, 2012Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Charles R. Cantor, Chunming Din
-
Publication number: 20110263453Abstract: Described herein are products and processes for nucleic acid quantification, which are in part useful for detecting and determining the nucleotide sequence of rare nucleic acids (i.e., low copy number nucleic acids) in a sample. Such products and processes are useful for reducing the dynamic range among different nucleic acid species.Type: ApplicationFiled: November 20, 2009Publication date: October 27, 2011Applicant: SEQUENOM, INC.Inventor: Charles R. Cantor
-
Patent number: 8034567Abstract: The present invention relates to a method for measuring the amount of a target nucleic acid in a sample using a standard which is designed to have one base difference compared with the gene of interest or a “target nucleic acid sequence.” Use of such standard in combination with a method of “enhancing” the difference in the standard and the test nucleic acid sample using, for example, a base extension reaction carried right at the mutation site allowing amplification of the standard and target nucleic acids with the same efficiency and facilitating quantification of the target nucleic acid. Thereafter a means of quantifying the “enhanced” standard and target nucleic acid samples is used to determine the amount of the target nucleic acid. In the preferred embodiment, the quantification means is Mass Spectrometry.Type: GrantFiled: September 5, 2003Date of Patent: October 11, 2011Assignee: Trustees of Boston UniversityInventors: Charles R. Cantor, Chunming Ding
-
Publication number: 20110244451Abstract: Chromosomal abnormalities are responsible for a significant number of birth defects, including mental retardation. The present invention is related to methods for non-invasive and rapid, prenatal diagnosis of chromosomal abnormalities based on analysis of a maternal blood sample. The invention exploits the differences in DNA between the mother and fetus, for instance differences in their methylation states, as a means to enrich for fetal DNA in maternal plasma sample. The methods described herein can be used to detect chromosomal DNA deletions and duplications. In a preferred embodiment, the methods are used to diagnose chromosomal aneuploidy and related disorders, such as Down's and Turner's Syndrome.Type: ApplicationFiled: July 27, 2010Publication date: October 6, 2011Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Charles R. Cantor, Chunming Ding
-
Patent number: 7999095Abstract: The present invention is directed to novel methods for in vitro and in vivo detection of target nucleic acid molecules, including DNA and RNA targets, as well as nucleic acid analogues. The present invention is based on protein complementation, in which two individual polypeptides are inactive. When the two inactive polypeptide fragment are brought in close proximity during hybridization to a target nucleic acid, they re-associate into an active, detectable protein.Type: GrantFiled: December 15, 2009Date of Patent: August 16, 2011Assignee: The Trustees of Boston UniversityInventors: Charles R. Cantor, Natalia E. Broude, Carlos Witte-Hoffman
-
Publication number: 20110124518Abstract: Provided herein are compositions and methods for analysis of nucleic acids, including, methods and compositions for genotyping, haplotyping, sequencing and performing other genetic and epigenetic analyses on nucleic acids, for example. In some embodiments, methods and compositions suitable for whole-genome sequencing on single molecules of nucleic acid are provided. In some embodiments, analysis of single molecules of nucleic acid are performed in conjunction with nanopores and/or nanopore devices.Type: ApplicationFiled: January 16, 2009Publication date: May 26, 2011Applicant: SEQUENOM, INC.Inventor: Charles R. Cantor
-
Publication number: 20110097712Abstract: The present invention is directed to a method for detecting and quantifying rare mutations in a nucleic acid sample. The nucleic acid molecules under investigation can be either DNA or RNA. The rare mutation can be any type of functional or non-functional nucleic acid change or mutation, such as deletion, insertion, translocation, inversion, one or more base substitution or polymorphism. Therefore, the methods of the present invention are useful in detection of rare mutations in, for example, diagnostic, prognostic and follow-up applications, when the targets are rare known nucleic acid variants mixed in with the wildtype or the more common nucleic acid variant(s).Type: ApplicationFiled: July 1, 2009Publication date: April 28, 2011Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Charles R. Cantor, Chunming Ding
-
Publication number: 20100297629Abstract: The present invention is directed to novel methods for in vitro and in vivo detection of target nucleic acid molecules, including DNA and RNA targets, as well as nucleic acid analogues. The present invention is based on protein complementation, in which two individual polypeptides are inactive. When the two inactive polypeptide fragment are brought in close proximity during hybridization to a target nucleic acid, they re-associate into an active, detectable protein.Type: ApplicationFiled: December 15, 2009Publication date: November 25, 2010Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Charles R. Cantor, Natalia E. Broude, Carlos Witte-Hoffman
-
Publication number: 20100255558Abstract: The invention relates to supramolecular bioconjugates and to methods for assembling and utilizing supramolecular bioconjugates. Supramolecular bioconjugates comprise a plurality of first nucleic acids and a plurality of mediators wherein each mediator comprises a second nucleic acid complementary to a sequence within said plurality of first nucleic acids. To assemble a supramolecular bioconjugate, one or more sets of bioreactive agents are coupled to the plurality of mediators, forming a plurality of bioreactive complexes. The plurality of bioreactive complexes are hybridized to the plurality of first nucleic acids to form the supramolecular bioconjugate. Bioconjugates can be used to detect and isolate targets, to screen samples for targets such as antigens, to treat patients with multiple agents or to diagnose disorders in the form of a kit.Type: ApplicationFiled: May 5, 2009Publication date: October 7, 2010Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Christof M. Niemeyer, Charles R. Cantor, Takeshi Sano, Cassandra L. Smith
-
Patent number: 7807375Abstract: The present invention provides a method for determining nucleic acid sequences of a template nucleic acid that requires no prior knowledge of the nucleic acid sequence present in the template nucleic acid. The method is based on combining information about the mass of a fragment, the mass of any one nucleotide and the combinations thereof, and the sequence specificity of a nucleotide cutter, either enzymatic or chemical cutter, to determine a sequence of a nucleic acid fragment. This method allows for de novo detection of sequences in a target nucleic acid without requiring any prior sequence information. This method is called Partial Sequencing by Fragmentation (PSBF) and it works by fragmenting a target into oligo- or polynucleotides whose masses or lengths are uniquely associated with known sequences. The identities of these sequences are determined solely by the specific fragmentation method used, and are always independent of the target.Type: GrantFiled: October 28, 2008Date of Patent: October 5, 2010Assignee: Trustees of Boston UniversityInventors: Charles R Cantor, Fouad A Siddiqi
-
Patent number: 7785798Abstract: Chromosomal abnormalities are responsible for a significant number of birth defects, including mental retardation. The present invention is related to methods for non-invasive and rapid, prenatal diagnosis of chromosomal abnormalities based on analysis of a maternal blood sample. The invention exploits the differences in DNA between the mother and fetus, for instance differences in their methylation states, as a means to enrich for fetal DNA in maternal plasma sample. The methods described herein can be used to detect chromosomal DNA deletions and duplications. In a preferred embodiment, the methods are used to diagnose chromosomal aneuploidy and related disorders, such as Down's and Turner's Syndrome.Type: GrantFiled: September 3, 2009Date of Patent: August 31, 2010Assignee: Trustees of Boston UniversityInventors: Charles R Cantor, Chunming Ding
-
Publication number: 20100184075Abstract: The present invention provides an efficient way for high throughput haplotype analysis. Several polymorphic nucleic acid markers, such as SNPs, can be simultaneously and reliably determined through multiplex PCR of single nucleic acid molecules in several parallel single molecule dilutions and the consequent statistical analysis of the results from these parallel single molecule multiplex PCR reactions results in reliable determination of haplotypes present in the subject. The nucleic acid markers can be of any distance to each other on the chromosome. In addition, an approach wherein overlapping DNA markers are analyzed can be used to link smaller haplotypes into larger haplotypes. Consequently, the invention provides a powerful new tool for diagnostic haplotyping and identifying novel haplotypes.Type: ApplicationFiled: February 11, 2010Publication date: July 22, 2010Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Charles R. Cantor, Chunming Ding
-
Patent number: 7709262Abstract: The present invention is directed to a method for detecting and quantifying rare mutations in a nucleic acid sample. The nucleic acid molecules under investigation can be either DNA or RNA. The rare mutation can be any type of functional or non-functional nucleic acid change or mutation, such as deletion, insertion, translocation, inversion, one or more base substitution or polymorphism. Therefore, the methods of the present invention are useful in detection of rare mutations in, for example, diagnostic, prognostic and follow-up applications, when the targets are rare known nucleic acid variants mixed in with the wildtype or the more common nucleic acid variant(s).Type: GrantFiled: February 18, 2005Date of Patent: May 4, 2010Assignee: Trustees of Boston UniversityInventors: Charles R. Cantor, Chunming Ding
-
Patent number: 7700325Abstract: The present invention provides an efficient way for high throughput haplotype analysis. Several polymorphic nucleic acid markers, such as SNPs, can be simultaneously and reliably determined through multiplex PCR of single nucleic acid molecules in several parallel single molecule dilutions and the consequent statistical analysis of the results from these parallel single molecule multiplex PCR reactions results in reliable determination of haplotypes present in the subject. The nucleic acid markers can be of any distance to each other on the chromosome. In addition, an approach wherein overlapping DNA markers are analyzed can be used to link smaller haplotypes into larger haplotypes. Consequently, the invention provides a powerful new tool for diagnostic haplotyping and identifying novel haplotypes.Type: GrantFiled: January 16, 2004Date of Patent: April 20, 2010Assignee: Trustees of Boston UniversityInventors: Charles R Cantor, Chunming Ding
-
Patent number: 7662554Abstract: The present invention is directed to novel methods for in vitro and in vivo detection of target nucleic acid molecules, including DNA and RNA targets, as well as nucleic acid analogues. The present invention is based on protein complementation, in which two individual polypeptides are inactive. When the two inactive polypeptide fragment are brought in close proximity during hybridization to a target nucleic acid, they re-associate into an active, detectable protein.Type: GrantFiled: October 9, 2003Date of Patent: February 16, 2010Assignee: The Trustees of Boston UniversityInventors: Charles R. Cantor, Natalia E. Broude, Carlos Witte-Hoffmann